Key Highlights
- Shares of AKTX skyrocketed 120% during after-hours trading after the company unveiled promising preclinical results for AKTX-101, its primary cancer therapeutic candidate
- The experimental drug demonstrated powerful synergistic anti-tumor effects when paired with the KRAS inhibitor adagrasib in pancreatic cancer testing models
- This synergistic effect appears exclusive to AKTX-101, as competing first-generation TROP2 ADCs displayed antagonistic interactions with adagrasib instead
- The company aims to initiate Phase 1 human trials for AKTX-101 around mid-2027
- Even after Thursday’s rally, AKTX remains approximately 55% lower year-to-date, trading with a market capitalization of only $5.77 million
Shares of Akari Therapeutics (AKTX) soared 120% during Thursday’s extended trading session following the company’s announcement of preclinical findings that suggest its primary drug candidate, AKTX-101, could offer a significant advantage in addressing difficult-to-treat pancreatic malignancies.
The experimental therapy — an antibody-drug conjugate (ADC) designed to target the Trop2 receptor — underwent testing alongside adagrasib, which inhibits KRAS. The company shared these findings through an ASCO abstract presentation.
When tested against pancreatic cancer cell lines harboring KRAS G12C and G12D mutations, the combination of AKTX-101 and adagrasib delivered synergistic tumor cell destruction. This indicates the dual-drug approach outperformed each treatment administered independently.
The truly notable aspect of these findings lies in the contrasting performance of competing therapies. Established topoisomerase I-targeting TROP2 ADCs demonstrated antagonism — the opposite of synergy — when combined with adagrasib. The synergistic profile of AKTX-101 appears to stem from its innovative RNA spliceosome-modulating payload, designated as PH1.
According to Akari, PH1 operates by marking pre-mRNA transcripts for elimination, including those containing the KRAS mutations that fuel these cancers. This represents a fundamentally different approach compared to most existing TROP2 ADCs in development.
The Implications of AKTX-101 for KRAS-Mutant Cancers
KRAS-mutant pancreatic cancer has remained among the most challenging malignancies in oncology. These new findings support the hypothesis that RNA splicing could represent a promising therapeutic avenue — and that AKTX-101’s payload differentiates it meaningfully from competitive therapies.
Akari stated that these results broaden the potential commercial opportunity for AKTX-101 beyond what was initially anticipated in its current Phase 1 development strategy.
The biotechnology firm has commenced IND-enabling studies and expects to launch Phase 1 first-in-human clinical trials by the middle of 2027.
Additionally, Akari maintains a second candidate in development: AKTX-102, an ADC that targets CEACAM5, an established tumor antigen. This program remains in earlier developmental stages.
Micro-Cap Company Posts Massive Percentage Gain
Akari operates as an extremely small biotechnology company. With a market capitalization of merely $5.77 million, it qualifies as a micro-cap stock. This diminutive size explains the magnitude of Thursday’s price movement; relatively modest trading volume can generate substantial percentage changes.
Four insider purchases have been documented during the past year, with zero insider sales recorded. While limited, this represents a positive indicator of management confidence.
Akari’s GF Score registers at only 22 out of 100, with profitability metrics scoring 1/10. The company generates no revenue and operates at a loss, which is standard for clinical-stage biotechnology firms.
Despite Thursday’s dramatic after-hours surge, AKTX shares remain down approximately 55% for the year. The stock had been experiencing a prolonged downturn prior to this data release.
With the Phase 1 trial launch targeted for mid-2027, investors face a considerable wait before any human efficacy data becomes available.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
